Taikang Life Insurance Invests in ClinChoice
Posted on 07/05/2022
Recently, ClinChoice Inc. announced the completion of its US$ 150 million Series E round financing. The investment was led by Legend Capital, and co-invested by Taikang Life Insurance, Sherpa Healthcare Partners, and existing shareholders, including Lilly Asia Ventures and Apricot Capital. Proceeds of the financing will be used to fund the company’s continued business expansion and innovative service offering worldwide.
As a full service clinical-stage CRO, ClinChoice serves the global market by providing integrated one-stop clinical development services to emerging biopharmaceutical, medical device, and consumer health clients around the world. ClinChoice has over 3,000 employees worldwide covering most of drug development hotbeds in U.S., China, multiple countries in Europe, and Southeast Asia.
